Savara Inc
Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole product candidate, MOLBREEVI (molgramostim inhalation solution), is an investigational inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis, a rare lung disease. The… From the company’s description.
In fiscal 2025, Savara Inc reported a net loss of $118.84M. Operations used $101.04M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Savara Inc does
In the company’s own words
Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole product candidate, MOLBREEVI (molgramostim inhalation solution), is an investigational inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis, a rare lung disease. The drug-device combination delivers recombinant human GM-CSF once daily using a proprietary eFlow nebulizer system. The FDA filed Savara’s biologics license application in February 2026 and granted it Priority Review. Savara also provides molgramostim through expanded access in select geographies and has global rights to the candidate; it is pursuing potential approvals in the United States, European Union and United Kingdom. The company outsources clinical development and manufacturing, working with contract research and manufacturing organizations and PARI for the nebulizer system, and has no commercial sales organization. Savara’s business centers on this single program rather than multiple reportable segments. Its website is www.savarapharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1160308
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Savara Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Savara Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Savara Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Savara Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Savara Inc's last four quarterly filings that the numbers alone won't show?”